The European diagnostic biomarker market is estimated to grow significantly at a CAGR of more than 11% during the forecast period. Factors that are contributing significantly in the market growth include the presence of a well-developed healthcare sector and considerably high healthcare expenditure and infrastructure in its economies such as Germany, UK, France and many more. The major factor contributing to the European diagnostic biomarker market include the rising prevalence of chronic diseases such as heart disease, cancer, diabetes, stroke, and arthritis. Unhealthy lifestyle such as smoking, consumption of drugs and alcohol in European countries are the major factors for increasing cancer incidences among men and women. Government initiatives, programs, and funding related to increasing awareness of cancer are also contributing to the growth of the market in the region. 

The European diagnostic biomarker market is segmented on the basis of diagnostic technique and application. On the basis of the diagnostic technique, the market is segmented into ELISA, colorimetric assay, liquid chromatography-mass spectrometry, particle-enhanced turbidimetric immunoassay and other. Further, on the basis of application, the market is segmented into oncology, cardiology, neurology, nephrology, and others. There is a huge scope for the market in the oncology segment due to the increasing prevalence of cancer. A large number of researches are going on finding a diagnostic biomarker for various types of cancer so that early detection can be done.

The major players in the European diagnostic biomarker market include Abbott Laboratories, Inc., Thermo Fisher Scientific, inc., F. Hoffmann-La Roche Ltd., Evotec AG, Becton Dickinson and Co., Qiagen NV, Novartis AG, and others. These companies are launching innovative products in the market, in order to meet the increasing demand for an effective diagnostic biomarker for cancer and cardiovascular diseases. Furthermore, the market players are adopting various strategies, in order to sustain in the competitive market, which includes partnership and collaboration, and investments. For instance, in October 2018, Evotec AG established a strategic research alliance with Sanofi. This partnership was aimed at introducing newly developed BRIDGE, named LAB031. It was designed to encourage drug discovery across multiple therapeutic areas. Moreover, it enabled the company to access resources to establish partnerships with academic institutions globally, which will allow addressing indications across several areas of disease.

Research Methodology

The market study of the European diagnostic biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for healthcare companies, research institutes, hospitals, pharmaceutical, and biotechnology companies, potential investors and venture capitalists, government organizations, and other market participants for the overall market and competitive analysis. The report provides an in-depth analysis of the market size and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. European Diagnostic Biomarker Market Research and Analysis by Diagnostic Technique
2. European Diagnostic Biomarker Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the European Diagnostic Biomarker Market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the European Diagnostic Biomarker Market.
• Insights about market determinants which are stimulating the European Diagnostic Biomarker Market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.